Study wrapper · #939

Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.

Pallavi K, Chandra A, Kumar K, et al. Maedica. 2025.

DOI: 10.26574/maedica.2025.20.4.824PubMed: 41537067

SupportedMeta-analysisMentions: Retatrutide

Editor's note

This systematic review pools eight randomized trials and reports substantial glycemic and weight reductions with retatrutide in a comorbid CKD population, plus a signal toward reduced albuminuria. An interesting dose-response pattern is noted, with lower doses appearing more effective for glycemic control. Gastrointestinal tolerability is the main safety consideration.

Plain-language abstract

A meta-analysis of eight trials found that retatrutide was associated with meaningful reductions in HbA1c and body weight in people with diabetes and/or obesity who also had chronic kidney disease, with mostly gastrointestinal side effects.

Mixed